相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1994
已完成
1
100.0%
暂无批准数据
- MB-204 demonstrated statistically significant restoration of behavioural and cognitive function toward wild-type levels in a Fragile X syndrome (Fmr1 KO) mouse model across all endpoints tested. - The high-dose group achieved wildtype-like performance in open-field activity, self-grooming, nesting, and hyponeophagia (p<0.0001 vs KO vehicle), with durable carry-over effects persisting two weeks after treatment cessation. - This represents the third independent preclinical autism spectrum disorder model in which MB-204 has shown efficacy, following positive results in Rett syndrome (Mecp2) and Oprm1 ASD models. - The study was conducted through the FRAXA Drug Validation Initiative, an independent program evaluating promising therapeutic candidates for Fragile X syndrome, an orphan disease affecting approximately 1 in 7,000 males.
- Oswald Steward of UC Irvine shares the 2026 Kavli Prize in Neuroscience with three other researchers for discovering local protein translation at synapses. - His electron microscopy studies revealed that neurons produce proteins locally where needed, transforming understanding of brain plasticity, learning, and memory. - The discovery has advanced research into fragile X syndrome, autism spectrum disorder, ALS, and brain and spinal cord injury. - The prize, administered by the Norwegian Academy of Science and Letters, includes $1 million and will be presented at a September ceremony in Oslo.
